Physician profile
Elliot Smith
NPI 1548559081
$7,830.28
in general payments reported to CMS, 2019-2025
38 companies · $2,709 in 2025
The $2,709 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $382 · 2021: $755 · 2022: $756 · 2023: $964 · 2024: $1,508 · 2025: $2,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,181.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,261.12 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Janssen Biotech, INC. | $1,034.61 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $727.00 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $654.47 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $422.52 | 2022-2025 | |
| Celgene Corporation | $341.97 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $302.91 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $278.66 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $162.64 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $158.76 | 2019-2022 | |
| Daiichi Sankyo INC. | $139.84 | 2019-2023 | Injectafer |
| Pfizer INC. | $123.00 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $118.16 | 2024-2025 | Vowst, Zenpep |
| Intercept Pharmaceuticals, INC. | $108.33 | 2019-2025 | Ocaliva |
| Braintree Laboratories, INC. | $106.38 | 2019-2023 | Sutab, Suflave |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $98.14 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $96.70 | 2021-2023 | |
| Medtronic, INC. | $82.14 | 2025 | Gi Genius |
| Merck Sharp & Dohme LLC | $62.08 | 2019-2023 | Dificid |
| Amgen INC. | $60.10 | 2022-2023 | Amjevita |
| Novo Nordisk INC | $54.65 | 2025 | Wegovy |
| Lilly USA, LLC | $53.08 | 2025 | Omvoh |
| Alexion Pharmaceuticals, INC. | $49.62 | 2019 | |
| Madrigal Pharmaceuticals | $49.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $46.08 | 2025 | Vegzelma |
| Organon LLC | $32.74 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $26.48 | 2024 | |
| Enterra Medical, INC. | $24.69 | 2023 | |
| Shire North American Group INC | $18.67 | 2019 | |
| Sandoz INC. | $18.18 | 2025 | Hyrimoz |
| Redhill Biopharma INC. | $17.15 | 2021 | |
| Pharmacosmos Therapeutics INC. | $16.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.35 | 2023 | Cyltezo |
| Romark Laboratories, Lc | $15.09 | 2020 | |
| Phadia US INC. | $14.78 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.80 | 2022 | |
| Endogastric Solutions, INC | $12.66 | 2024 | Esophyx |
| Allergan, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.